395 related articles for article (PubMed ID: 22549947)
1. Epigenetic resensitization to platinum in ovarian cancer.
Matei D; Fang F; Shen C; Schilder J; Arnold A; Zeng Y; Berry WA; Huang T; Nephew KP
Cancer Res; 2012 May; 72(9):2197-205. PubMed ID: 22549947
[TBL] [Abstract][Full Text] [Related]
2. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
5. Decitabine reactivated pathways in platinum resistant ovarian cancer.
Fang F; Zuo Q; Pilrose J; Wang Y; Shen C; Li M; Wulfridge P; Matei D; Nephew KP
Oncotarget; 2014 Jun; 5(11):3579-89. PubMed ID: 25003579
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S; Hu W; Iyer R; Kavanagh JJ; Coleman RL; Levenback CF; Sood AK; Wolf JK; Gershenson DM; Markman M; Hennessy BT; Kurzrock R; Bast RC
Cancer; 2011 Apr; 117(8):1661-9. PubMed ID: 21472713
[TBL] [Abstract][Full Text] [Related]
7. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
[TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Dizon DS; Blessing JA; Penson RT; Drake RD; Walker JL; Johnston CM; Disilvestro PA; Fader AN
Gynecol Oncol; 2012 May; 125(2):367-71. PubMed ID: 22366594
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Matei D; Ghamande S; Roman L; Alvarez Secord A; Nemunaitis J; Markham MJ; Nephew KP; Jueliger S; Oganesian A; Naim S; Su XY; Keer H; Azab M; Fleming GF
Clin Cancer Res; 2018 May; 24(10):2285-2293. PubMed ID: 29500276
[No Abstract] [Full Text] [Related]
11. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
[TBL] [Abstract][Full Text] [Related]
15. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
18. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
[TBL] [Abstract][Full Text] [Related]
20. Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Fu X; Zhang Y; Wang X; Chen M; Wang Y; Nie J; Meng Y; Han W
Curr Protein Pept Sci; 2015; 16(4):329-36. PubMed ID: 25929868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
